The assessment of biologic treatment in patients with rheumatoid arthritis using FDG-PET/CT
To evaluate whether there is a correlation between the differences in joint uptake of 2-[18F]-fluoro-2-deoxy-d-glucose ((18)F-FDG) and the improvement of clinical findings in RA patients undergoing anti-TNF therapies. Twenty-two patients who received anti-TNF therapies, including infliximab for 16 p...
Gespeichert in:
| Veröffentlicht in: | Rheumatology (Oxford, England) England), 2012-08, Vol.51 (8), p.1484-1491 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1491 |
|---|---|
| container_issue | 8 |
| container_start_page | 1484 |
| container_title | Rheumatology (Oxford, England) |
| container_volume | 51 |
| creator | OKAMURA, Koichi YONEMOTO, Yukio ARISAKA, Yukiko TAKEUCHI, Kimihiko KOBAYASHI, Tsutomu ORIUCHI, Noboru TSUSHIMA, Yoshito TAKAGISHI, Kenji |
| description | To evaluate whether there is a correlation between the differences in joint uptake of 2-[18F]-fluoro-2-deoxy-d-glucose ((18)F-FDG) and the improvement of clinical findings in RA patients undergoing anti-TNF therapies.
Twenty-two patients who received anti-TNF therapies, including infliximab for 16 patients and etanercept for 6 patients, were assessed. PET with (18)F-FDG studies and clinical assessments were performed at baseline and 6 months after the initiation of therapy. The maximal standardized uptake value (SUV(max)) was used as a representative value for the assessment of the FDG uptake in the bilateral shoulder, elbow, wrist, hip, knee and ankle joints. Spearman's rank correlation test was applied to assess the correlation between the SUV and the clinical parameters.
The ΔSUV (12 joints), the difference in the SUV(max) of the affected 12 joints before and after treatment, was positively correlated with the ΔDAS28 (r = 0.609, P = 0.003), ΔDAS28-CRP (r = 0.656, P = 0.001) and Δtender joint count (TJC) (r = 0.609, P = 0.003). There were also significantly positive correlations between ΔSUV (8 joints); the difference in the SUV(max) of the bilateral shoulder, elbow, wrist and knee joints before and after treatment and the ΔDAS28 (r = 0.642, P = 0.001), ΔDAS28-CRP (r = 0.712, P |
| doi_str_mv | 10.1093/rheumatology/kes064 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1026863262</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1026863262</sourcerecordid><originalsourceid>FETCH-LOGICAL-c380t-fe1e9b0b6b4197dd3391b09edc093a535b79ba3cb9d7f46bc85e3370a345b9423</originalsourceid><addsrcrecordid>eNpNkElPwzAQhS0EYv8FSMgXJC6htidLfUSlLUhIcCgnDpHtOI0hS_E4Qv33pLQsp3kafe-N5hFywdkNZxJGvrJ9o0JXd8v16N0iS-M9cszjVEQMQOz_ahEfkRPEN8ZYwmF8SI6EGASPk2PyuqgsVYgWsbFtoF1JtdtEOkODtyp8b11LVyq4QSL9dKGiP7ddQZUPlXfBIe3RtUs6u5tHz9PFaLI4IwelqtGe7-YpeZlNF5P76PFp_jC5fYwMjFmISsut1EynOuYyKwoAyTWTtjDDlyqBRGdSKzBaFlkZp9qMEwuQMQVxomUs4JRcb3NXvvvoLYa8cWhsXavWdj3mnIl0nIJINyhsUeM7RG_LfOVdo_x6gPJNq_n_VvNtq4Prcneg140tfj0_NQ7A1Q5QaFRdetUah39cyqUQwOALRfGFVw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1026863262</pqid></control><display><type>article</type><title>The assessment of biologic treatment in patients with rheumatoid arthritis using FDG-PET/CT</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>OKAMURA, Koichi ; YONEMOTO, Yukio ; ARISAKA, Yukiko ; TAKEUCHI, Kimihiko ; KOBAYASHI, Tsutomu ; ORIUCHI, Noboru ; TSUSHIMA, Yoshito ; TAKAGISHI, Kenji</creator><creatorcontrib>OKAMURA, Koichi ; YONEMOTO, Yukio ; ARISAKA, Yukiko ; TAKEUCHI, Kimihiko ; KOBAYASHI, Tsutomu ; ORIUCHI, Noboru ; TSUSHIMA, Yoshito ; TAKAGISHI, Kenji</creatorcontrib><description>To evaluate whether there is a correlation between the differences in joint uptake of 2-[18F]-fluoro-2-deoxy-d-glucose ((18)F-FDG) and the improvement of clinical findings in RA patients undergoing anti-TNF therapies.
Twenty-two patients who received anti-TNF therapies, including infliximab for 16 patients and etanercept for 6 patients, were assessed. PET with (18)F-FDG studies and clinical assessments were performed at baseline and 6 months after the initiation of therapy. The maximal standardized uptake value (SUV(max)) was used as a representative value for the assessment of the FDG uptake in the bilateral shoulder, elbow, wrist, hip, knee and ankle joints. Spearman's rank correlation test was applied to assess the correlation between the SUV and the clinical parameters.
The ΔSUV (12 joints), the difference in the SUV(max) of the affected 12 joints before and after treatment, was positively correlated with the ΔDAS28 (r = 0.609, P = 0.003), ΔDAS28-CRP (r = 0.656, P = 0.001) and Δtender joint count (TJC) (r = 0.609, P = 0.003). There were also significantly positive correlations between ΔSUV (8 joints); the difference in the SUV(max) of the bilateral shoulder, elbow, wrist and knee joints before and after treatment and the ΔDAS28 (r = 0.642, P = 0.001), ΔDAS28-CRP (r = 0.712, P < 0.001) and ΔTJC (r = 0.608, P = 0.003), respectively.
The FDG uptake observed in the inflamed RA joints may reflect disease activity. The FDG-PET response was correlated with the clinical response to the biologic treatment of RA.</description><identifier>ISSN: 1462-0324</identifier><identifier>EISSN: 1462-0332</identifier><identifier>DOI: 10.1093/rheumatology/kes064</identifier><identifier>PMID: 22513145</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Adult ; Aged ; Antibodies, Monoclonal - administration & dosage ; Antirheumatic Agents - administration & dosage ; Arthritis, Rheumatoid - diagnostic imaging ; Arthritis, Rheumatoid - drug therapy ; Biological and medical sciences ; Diseases of the osteoarticular system ; Etanercept ; Female ; Fluorodeoxyglucose F18 ; Follow-Up Studies ; Humans ; Immunoglobulin G - administration & dosage ; Inflammatory joint diseases ; Infliximab ; Male ; Medical sciences ; Middle Aged ; Multimodal Imaging - methods ; Positron-Emission Tomography ; Radiopharmaceuticals ; Receptors, Tumor Necrosis Factor - administration & dosage ; Severity of Illness Index ; Tomography, X-Ray Computed ; Treatment Outcome ; Tumor Necrosis Factor-alpha - antagonists & inhibitors ; Young Adult</subject><ispartof>Rheumatology (Oxford, England), 2012-08, Vol.51 (8), p.1484-1491</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c380t-fe1e9b0b6b4197dd3391b09edc093a535b79ba3cb9d7f46bc85e3370a345b9423</citedby><cites>FETCH-LOGICAL-c380t-fe1e9b0b6b4197dd3391b09edc093a535b79ba3cb9d7f46bc85e3370a345b9423</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26192230$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22513145$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>OKAMURA, Koichi</creatorcontrib><creatorcontrib>YONEMOTO, Yukio</creatorcontrib><creatorcontrib>ARISAKA, Yukiko</creatorcontrib><creatorcontrib>TAKEUCHI, Kimihiko</creatorcontrib><creatorcontrib>KOBAYASHI, Tsutomu</creatorcontrib><creatorcontrib>ORIUCHI, Noboru</creatorcontrib><creatorcontrib>TSUSHIMA, Yoshito</creatorcontrib><creatorcontrib>TAKAGISHI, Kenji</creatorcontrib><title>The assessment of biologic treatment in patients with rheumatoid arthritis using FDG-PET/CT</title><title>Rheumatology (Oxford, England)</title><addtitle>Rheumatology (Oxford)</addtitle><description>To evaluate whether there is a correlation between the differences in joint uptake of 2-[18F]-fluoro-2-deoxy-d-glucose ((18)F-FDG) and the improvement of clinical findings in RA patients undergoing anti-TNF therapies.
Twenty-two patients who received anti-TNF therapies, including infliximab for 16 patients and etanercept for 6 patients, were assessed. PET with (18)F-FDG studies and clinical assessments were performed at baseline and 6 months after the initiation of therapy. The maximal standardized uptake value (SUV(max)) was used as a representative value for the assessment of the FDG uptake in the bilateral shoulder, elbow, wrist, hip, knee and ankle joints. Spearman's rank correlation test was applied to assess the correlation between the SUV and the clinical parameters.
The ΔSUV (12 joints), the difference in the SUV(max) of the affected 12 joints before and after treatment, was positively correlated with the ΔDAS28 (r = 0.609, P = 0.003), ΔDAS28-CRP (r = 0.656, P = 0.001) and Δtender joint count (TJC) (r = 0.609, P = 0.003). There were also significantly positive correlations between ΔSUV (8 joints); the difference in the SUV(max) of the bilateral shoulder, elbow, wrist and knee joints before and after treatment and the ΔDAS28 (r = 0.642, P = 0.001), ΔDAS28-CRP (r = 0.712, P < 0.001) and ΔTJC (r = 0.608, P = 0.003), respectively.
The FDG uptake observed in the inflamed RA joints may reflect disease activity. The FDG-PET response was correlated with the clinical response to the biologic treatment of RA.</description><subject>Adult</subject><subject>Aged</subject><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Antirheumatic Agents - administration & dosage</subject><subject>Arthritis, Rheumatoid - diagnostic imaging</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Biological and medical sciences</subject><subject>Diseases of the osteoarticular system</subject><subject>Etanercept</subject><subject>Female</subject><subject>Fluorodeoxyglucose F18</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Immunoglobulin G - administration & dosage</subject><subject>Inflammatory joint diseases</subject><subject>Infliximab</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multimodal Imaging - methods</subject><subject>Positron-Emission Tomography</subject><subject>Radiopharmaceuticals</subject><subject>Receptors, Tumor Necrosis Factor - administration & dosage</subject><subject>Severity of Illness Index</subject><subject>Tomography, X-Ray Computed</subject><subject>Treatment Outcome</subject><subject>Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><subject>Young Adult</subject><issn>1462-0324</issn><issn>1462-0332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkElPwzAQhS0EYv8FSMgXJC6htidLfUSlLUhIcCgnDpHtOI0hS_E4Qv33pLQsp3kafe-N5hFywdkNZxJGvrJ9o0JXd8v16N0iS-M9cszjVEQMQOz_ahEfkRPEN8ZYwmF8SI6EGASPk2PyuqgsVYgWsbFtoF1JtdtEOkODtyp8b11LVyq4QSL9dKGiP7ddQZUPlXfBIe3RtUs6u5tHz9PFaLI4IwelqtGe7-YpeZlNF5P76PFp_jC5fYwMjFmISsut1EynOuYyKwoAyTWTtjDDlyqBRGdSKzBaFlkZp9qMEwuQMQVxomUs4JRcb3NXvvvoLYa8cWhsXavWdj3mnIl0nIJINyhsUeM7RG_LfOVdo_x6gPJNq_n_VvNtq4Prcneg140tfj0_NQ7A1Q5QaFRdetUah39cyqUQwOALRfGFVw</recordid><startdate>20120801</startdate><enddate>20120801</enddate><creator>OKAMURA, Koichi</creator><creator>YONEMOTO, Yukio</creator><creator>ARISAKA, Yukiko</creator><creator>TAKEUCHI, Kimihiko</creator><creator>KOBAYASHI, Tsutomu</creator><creator>ORIUCHI, Noboru</creator><creator>TSUSHIMA, Yoshito</creator><creator>TAKAGISHI, Kenji</creator><general>Oxford University Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120801</creationdate><title>The assessment of biologic treatment in patients with rheumatoid arthritis using FDG-PET/CT</title><author>OKAMURA, Koichi ; YONEMOTO, Yukio ; ARISAKA, Yukiko ; TAKEUCHI, Kimihiko ; KOBAYASHI, Tsutomu ; ORIUCHI, Noboru ; TSUSHIMA, Yoshito ; TAKAGISHI, Kenji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c380t-fe1e9b0b6b4197dd3391b09edc093a535b79ba3cb9d7f46bc85e3370a345b9423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Antirheumatic Agents - administration & dosage</topic><topic>Arthritis, Rheumatoid - diagnostic imaging</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Biological and medical sciences</topic><topic>Diseases of the osteoarticular system</topic><topic>Etanercept</topic><topic>Female</topic><topic>Fluorodeoxyglucose F18</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Immunoglobulin G - administration & dosage</topic><topic>Inflammatory joint diseases</topic><topic>Infliximab</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multimodal Imaging - methods</topic><topic>Positron-Emission Tomography</topic><topic>Radiopharmaceuticals</topic><topic>Receptors, Tumor Necrosis Factor - administration & dosage</topic><topic>Severity of Illness Index</topic><topic>Tomography, X-Ray Computed</topic><topic>Treatment Outcome</topic><topic>Tumor Necrosis Factor-alpha - antagonists & inhibitors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>OKAMURA, Koichi</creatorcontrib><creatorcontrib>YONEMOTO, Yukio</creatorcontrib><creatorcontrib>ARISAKA, Yukiko</creatorcontrib><creatorcontrib>TAKEUCHI, Kimihiko</creatorcontrib><creatorcontrib>KOBAYASHI, Tsutomu</creatorcontrib><creatorcontrib>ORIUCHI, Noboru</creatorcontrib><creatorcontrib>TSUSHIMA, Yoshito</creatorcontrib><creatorcontrib>TAKAGISHI, Kenji</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Rheumatology (Oxford, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>OKAMURA, Koichi</au><au>YONEMOTO, Yukio</au><au>ARISAKA, Yukiko</au><au>TAKEUCHI, Kimihiko</au><au>KOBAYASHI, Tsutomu</au><au>ORIUCHI, Noboru</au><au>TSUSHIMA, Yoshito</au><au>TAKAGISHI, Kenji</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The assessment of biologic treatment in patients with rheumatoid arthritis using FDG-PET/CT</atitle><jtitle>Rheumatology (Oxford, England)</jtitle><addtitle>Rheumatology (Oxford)</addtitle><date>2012-08-01</date><risdate>2012</risdate><volume>51</volume><issue>8</issue><spage>1484</spage><epage>1491</epage><pages>1484-1491</pages><issn>1462-0324</issn><eissn>1462-0332</eissn><abstract>To evaluate whether there is a correlation between the differences in joint uptake of 2-[18F]-fluoro-2-deoxy-d-glucose ((18)F-FDG) and the improvement of clinical findings in RA patients undergoing anti-TNF therapies.
Twenty-two patients who received anti-TNF therapies, including infliximab for 16 patients and etanercept for 6 patients, were assessed. PET with (18)F-FDG studies and clinical assessments were performed at baseline and 6 months after the initiation of therapy. The maximal standardized uptake value (SUV(max)) was used as a representative value for the assessment of the FDG uptake in the bilateral shoulder, elbow, wrist, hip, knee and ankle joints. Spearman's rank correlation test was applied to assess the correlation between the SUV and the clinical parameters.
The ΔSUV (12 joints), the difference in the SUV(max) of the affected 12 joints before and after treatment, was positively correlated with the ΔDAS28 (r = 0.609, P = 0.003), ΔDAS28-CRP (r = 0.656, P = 0.001) and Δtender joint count (TJC) (r = 0.609, P = 0.003). There were also significantly positive correlations between ΔSUV (8 joints); the difference in the SUV(max) of the bilateral shoulder, elbow, wrist and knee joints before and after treatment and the ΔDAS28 (r = 0.642, P = 0.001), ΔDAS28-CRP (r = 0.712, P < 0.001) and ΔTJC (r = 0.608, P = 0.003), respectively.
The FDG uptake observed in the inflamed RA joints may reflect disease activity. The FDG-PET response was correlated with the clinical response to the biologic treatment of RA.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>22513145</pmid><doi>10.1093/rheumatology/kes064</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1462-0324 |
| ispartof | Rheumatology (Oxford, England), 2012-08, Vol.51 (8), p.1484-1491 |
| issn | 1462-0324 1462-0332 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1026863262 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; Alma/SFX Local Collection |
| subjects | Adult Aged Antibodies, Monoclonal - administration & dosage Antirheumatic Agents - administration & dosage Arthritis, Rheumatoid - diagnostic imaging Arthritis, Rheumatoid - drug therapy Biological and medical sciences Diseases of the osteoarticular system Etanercept Female Fluorodeoxyglucose F18 Follow-Up Studies Humans Immunoglobulin G - administration & dosage Inflammatory joint diseases Infliximab Male Medical sciences Middle Aged Multimodal Imaging - methods Positron-Emission Tomography Radiopharmaceuticals Receptors, Tumor Necrosis Factor - administration & dosage Severity of Illness Index Tomography, X-Ray Computed Treatment Outcome Tumor Necrosis Factor-alpha - antagonists & inhibitors Young Adult |
| title | The assessment of biologic treatment in patients with rheumatoid arthritis using FDG-PET/CT |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T05%3A30%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20assessment%20of%20biologic%20treatment%20in%20patients%20with%20rheumatoid%20arthritis%20using%20FDG-PET/CT&rft.jtitle=Rheumatology%20(Oxford,%20England)&rft.au=OKAMURA,%20Koichi&rft.date=2012-08-01&rft.volume=51&rft.issue=8&rft.spage=1484&rft.epage=1491&rft.pages=1484-1491&rft.issn=1462-0324&rft.eissn=1462-0332&rft_id=info:doi/10.1093/rheumatology/kes064&rft_dat=%3Cproquest_cross%3E1026863262%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1026863262&rft_id=info:pmid/22513145&rfr_iscdi=true |